Role of Bumetanide in Treatment of Autism
Overview
Role of bumetanide in Autism
Full Title of Study: “Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: December 1, 2030
Detailed Description
Role of Bumetanide in Treatment of Autism spectrum disorder in children
Interventions
- Drug: Bumetanide
- bumetanide 0.5 mg twice daily
- Drug: Placebo
- placebo tablets twice daily
Arms, Groups and Cohorts
- Experimental: bumetanide group
- Bumetanide a dose of 0.5 mg twice per day
- Placebo Comparator: Placebo
- Placebo twice daily
Clinical Trial Outcome Measures
Primary Measures
- Number of patients with improved CARS score
- Time Frame: 6 months
- the patients with improved CARS score
Participating in This Clinical Trial
Inclusion Criteria
1. All patients with ASD diagnosed by CARS rating Scale⩾30. 2. Age of patients range between (3-12) years. Exclusion Criteria:
- Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).
Gender Eligibility: All
Minimum Age: 3 Years
Maximum Age: 12 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Sherief Abd-Elsalam
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine – Tanta University
- Overall Official(s)
- Osama Elagamy, Prof, Principal Investigator, Pediatrics Department- Kafr-Elsheikh University
- Abeer Salamah, Dr, Study Director, Pediatrics Department- Kafr-Elsheikh University
- Esraa Shaker, Msc, Principal Investigator, Pediatrics Department- Kafr-Elsheikh University
- Overall Contact(s)
- Sherief Abd-Elsalam, ass. prof., 00201147773440, sheriefabdelsalam@yahoo.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.